AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors.
Sophia FrentzasSteven KaoRang GaoHao ZhengAhsan RizwanNageshwar BudhaLuz de la Hoz PedrozaWei TanTarek MeniawyPublished in: Journal for immunotherapy of cancer (2023)
NCT04047862.